TREATMENT OF PHILADELPHIA LEUKEMIA IN SEVERE COMBINED IMMUNODEFICIENTMICE BY COMBINATION OF CYCLOPHOSPHAMIDE AND BCR ABL ANTISENSE OLIGODEOXYNUCLEOTIDES/
T. Skorski et al., TREATMENT OF PHILADELPHIA LEUKEMIA IN SEVERE COMBINED IMMUNODEFICIENTMICE BY COMBINATION OF CYCLOPHOSPHAMIDE AND BCR ABL ANTISENSE OLIGODEOXYNUCLEOTIDES/, Journal of the National Cancer Institute, 89(2), 1997, pp. 124-133
Background: Philadelphia(1) cells are human chronic myelogenous leukem
ia (CML) cells that contain the BCR/ABL oncogene (a fusion of the BCR
and ABL genes). Selective eradication of these cells in vitro can be a
chieved by combined treatment with antisense phosphorothioate oligodeo
xynucleotides ([S]ODNs) specifically targeted to this oncogene (bcr/ab
l [S]ODNs) and a suboptimal (for use as a single agent) dose of mafosf
amide (the in vitro active form of cyclophosphamide). Purpose: We eval
uated the ability of bcr/ abl antisense [S]ODNs, alone or subsequent t
o treatment with a single injection of cyclophosphamide, to suppress t
he leukemic process induced in severe combined immunodeficient (SCID)
mice by Philadelphia(1) cells (i.e., primary CML-blast crisis [CML-BC]
cells). In addition, we studied potential mechanisms that might expla
in the efficacy of the bcr/abl antisense [S]ODN-mafosfamide combinatio
n against Philadelphia(1) cells in vitro. Methods: The effects of trea
ting leukemic mice with cyclophosphamide (25 mg/kg body weight; 25% of
the dose required to eradicate evidence of leukemia in SCID mice) and
/or bcr/abl antisense [S]ODNs were assessed by analysis of survival, b
y examination of bone marrow for the presence of leukemia cells (using
a colony formal ion assay or using coupled reverse transcription and
the polymerase chain reaction to screen for bcr/abl messenger RNA), an
d by examination of a variety of tissues for the presence of infiltrat
ing leukemia cells. The induction of apoptosis (a cell death program)
in vitro in primary CML-BC tells following treatment with bcr/abl anti
sense [S]ODNs plus or minus prior treatment with mafosfamide was monit
ored by use of a commercial assay. Relative cellular uptake of [S]ODNs
by CML-BC cells treated in vitro with or without prior treatment with
mafosfamide was determined by use of confocal microscopy and flow cyt
ometry (for fluorescent [S]ODNs) or by use of blotting techniques that
employed radioactively labeled probes (for extracted, unlabeled [S]OD
Ns). Levels of specific proteins in treated and untreated cells mere d
etermined by use of western blotting methods. Reported P values are tw
o-sided Results: The disease process in leukemic mice was retarded sub
stantially by combination treatment with cyclophosphamide and specific
bcr/abl antisense [S]ODNs (P<.001, relative to treatment with specifi
c antisense [S]ODNs alone, cyclophosphamide alone, or cyclophosphamide
plus nonspecific [i.e., control] antisense [S]ODNs); 50% of the mice
treated with cyclophosphamide and specific antisense [S]ODNs appeal ed
to be cured of leukemia. The combination treatment was associated wit
h increased induction of apoptosis, in addition, cellular uptake of bc
r/abl antisense [S]ODNs appeared to be increased twofold to sixfold by
prior treatment with mafosfamide. This increased uptake of [S]ODNs wa
s associated with enhanced suppression of p210(bcr/abl) protein levels
. Conclusions and Implications: Combination therapy with antisense [S]
ODNs targeted to specific oncogenes and less toxic doses of anticancer
drugs may represent a rational strategy to pursue for the treatment o
f human leukemias.